

Citation for published version:

Tillett, W, Adebajo, A, Brooke, M, Campbell, W, Coates, LC, Fitzgerald, O, Gossec, L, Helliwell, P, Hewlett, S, James, J, Minnock, P, Reast, A, O'Sullivan, D, de Wit, M & McHugh, N 2014, 'Patient involvement in outcome measures for psoriatic arthritis', *Current Rheumatology Reports*, vol. 16, no. 5, pp. 1-10.
<https://doi.org/10.1007/s11926-014-0418-7>

DOI:

[10.1007/s11926-014-0418-7](https://doi.org/10.1007/s11926-014-0418-7)

Publication date:

2014

Document Version

Early version, also known as pre-print

[Link to publication](#)

University of Bath

Alternative formats

If you require this document in an alternative format, please contact:
openaccess@bath.ac.uk

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Patient Involvement in Outcome Measures for Psoriatic Arthritis

W. Tillett, A. Adebajo, M. Brooke, W. Campbell, L. C. Coates, O. FitzGerald,
L. Gossec, P. Helliwell, S. Hewlett, J. James, P. Minnock, A. Reast, D.
O'Sullivan, M. de Wit, N. McHugh

Corresponding Author

Dr William Tillett MBChB, BSc, MRCP,
Royal National Hospital for Rheumatic Diseases,
Upper Borough Walls,
Bath,
BA11RL, UK.

Tel: 44 (0) 1225 448444 ext 2207

Mob: 07980960722

e-mail: w.tillett@nhs.net

Keywords: Psoriatic arthritis; Outcome measures; Assessment; Disease activity; Patient reported outcomes

Words 3538/4000, abstract 136

Other author details:

Ade Adebajo: FRCP a.o.adebajo@sheffield.ac.uk

Faculty of Medicine, Dentistry and Health, University of Sheffield, Beech Hill Road, Sheffield, S10 2RX, United Kingdom

Mel Brooke: brookem@btinternet.com

33 Coniston Road, Chippenham, Wiltshire SN14 0PX

Willemina Campbell B.A., B.Ed., LL.B. ina.campbell@sympatico.ca

21 James Speight Rd. Markham ON, Canada, L3P 3G3

Laura Coates MBChB PhD L.C.Coates@leeds.ac.uk

Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, UK

Oliver FitzGerald; MD, FRCPI, FRCP(UK) oliver.fitzgerald@ucd.ie

Dept Rheumatology, St Vincents University Hospital and Conway Institute of Biomolecular Research, University College Dublin, IRELAND

Laure Gossec, MD, PhD, UPMC laure.gossec@psl.aphp.fr

Univ Paris 06, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Department of rheumatology, Paris, France.

Philip Helliwell: DM PhD FRCP p.helliwell@leeds.ac.uk

Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, 2nd Floor, Chapel Allerton Hospital, Harehills Lane, Leeds, LS7 4SA

Sarah Hewlett FRCN, PhD, MA, RN; Sarah.Hewlett@uwe.ac.uk

Dept of Nursing and Midwifery, University of the West of England, Bristol

Jana James jjoyj21@live.co.uk

6 Silver Meadows, Torwbridge, Wiltshire, BA140LF

Patricia Minnock: BSc, MSc, PhD, RGN, PMinnock@olh.ie

University College Dublin Rheumatology Rehabilitation, Our Lady's Hospice,
Harold's Cross, Dublin, Ireland

Aisling Reast: BSc (Hons) DipPR, reast@eircom.net

The Pharmaceutical Society of Ireland, PSI House, Fenian Street, Dublin

Dennis O'Sullivan donncha123@yahoo.co.uk

Maarten de Wit, Maarten, MSc. martinusdewit@hotmail.com

VU Medical Center, department of medical humanities: Van der
Boechorststraat 7, 1081 BT Amsterdam, Netherlands

Neil McHugh MBChB, MD, FRACP, FRCP, FRCPath,

Neil.McHugh@rnhrd.nhs.uk

Royal National Hospital for Rheumatic Diseases, Upper Borough Walls, Bath,
BA11RL, UK

Abstract

Psoriatic arthritis (PsA) is a heterogeneous inflammatory arthritis with a varied clinical phenotype. There has been considerable international collaboration over recent years to develop and prioritise appropriate disease domains and outcome measures to capture all aspects of this complex disease. It has been recognised that patient reported measures and physician assessments are complementary and when used together allow an improved reflection of disease burden. Taking this concept one step further the experience in rheumatoid arthritis has demonstrated benefits of incorporating the patient perspective in the development of outcome measures. We report a systematic review demonstrating there has been little incorporation of the patient perspective in the development of outcome measures and domains in PsA, the proceedings from the preliminary patient involvement in outcome measures for PsA (PIOMPSA) meetings and a proposed roadmap for improving patient involvement.

Introduction

Psoriatic arthritis (PsA) is a complex disease with a varied clinical phenotype affecting the skin, joints, nails, entheses and axial skeleton. Historically disease outcome has been measured with tools adapted from related inflammatory diseases such as rheumatoid arthritis (RA) and axial spondyloarthritis.¹ It became apparent that such borrowed instruments did not capture all aspects of this multifaceted disease and considerable progress has been made in the development of disease domains and composite measures for PsA in recent years. The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) in collaboration with Outcome Measures in Rheumatology (OMERACT) have been actively involved with this process, defining appropriate domains of assessment and tools to measure them.^{2, 3}

An obvious way of capturing all components of PsA has been an expansion in the use of patient reported outcome (PRO) measures assessing health related quality of life, physical function, work, pain, fatigue and global health.^{1, 4} The use of PRO's arose from the realisation that the patient perspective brings a unique insight into the measurement of disease activity that was previously not captured by traditional, physician-centric outcome measures such as clinical examination and biomarkers. Moreover incorporating PRO's has the potential of reducing the impact of the known discordance in disease assessment between physician and patient, as demonstrated in RA^{5, 6} and PsA⁷. There is consensus that both PRO's and physician assessed measures

are required to effectively capture all aspects of disease and that this combined approach results in a truer reflection of disease and thus both are incorporated in the OMERACT core set for PsA.⁸

In recent years we have seen the PRO's concept extended to the incorporation of the patient perspective in the OMERACT process.⁹ Patients have brought a new perspective to how domains of disease should be prioritised and measured, thus enhancing the 'truth' aspect of the OMERACT filter.^{10, 11} The European League Against Rheumatism (EULAR) has also recognised this issue and recommends the inclusion of the patient perspective in scientific projects.^{12, 13} Furthermore the National Institute of Health Research (NIHR) in the United Kingdom has convened the INVOLVE group to promote patient involvement in all aspects of the NHS including research. Despite the growing recognition of the benefits of incorporating the patient perspective it has recently become apparent that there has been little patient involvement in the development of PsA domains and outcome measures. We report a systematic review of patient involvement in the development of outcome measures and domains in PsA, the proceedings from the preliminary GRAPPA special interest group for Patient Involvement in Outcome Measures for PsA (PIOMPSA) meetings and a proposed action plan for improving patient involvement.

Systematic review of patient involvement in PsA

We set out to establish the degree of patient involvement during the development of the original domain construct, outcome measure and disease activity indices used in psoriatic arthritis.

Methods

A literature search was performed of Medline and Embase (1970- present) and the Cochrane database on January 3rd 2013. Publications were identified using the following keyword or MeSH terms: “psoriatic arthritis” in combination with (AND) “Domain” OR “Outcome” OR “Assessment” OR “Validation” (AND) “Composite measure”, “physical function”, “skin activity”, “patient global”, “pain”, “health related quality of life”, “peripheral joint activity”, “enthesitis”, “dactylitis”, “fatigue”, “nails”, “physician global”, “spinal”, “participation” as listed in the OMERACT core set for PsA. Radiology, MRI, USS, CT, tissue analysis and acute phase reactants were not included in the search. The following limitations were applied; “Humans”, “English Language”, “published 1970 to present”.

Inclusion criteria: Any study developing an outcome measure or core set of outcome measures for use in PsA. *Exclusion criteria:* Review articles, conference abstracts, articles not reporting data specific to PsA, articles not reporting any clinical outcomes (such as genetic, radiographic or laboratory measures), articles not developing an outcome measure for use in PsA. *Data extraction;* Abstracts were screened for the presence of exclusion criteria and the remaining articles were subject to full text review. A ‘pearl growing’

approach was then employed. For each outcome measure found the first article validating or using an outcome measure in PsA was selected along with any citing articles (citation tracking) and their references (reference tracking). This approach was felt to be the most effective and efficient way of identifying the literature. Articles were screened and reviewed for using a literature evaluation tool. The tool was developed through consensus by the authors based upon the INVOLVE and EULAR guidelines for patient involvement in research.^{12, 14} The level and type of patient involvement was recorded; patient selection (for communication skills, motivation, constructive assertiveness), training (background information), consultation (patients consulted on their views through interview or focus groups), collaboration (on-going relationship such with the research team or advisory board), whether the research was user-led (patient directed and managed research) and finally recognition of the patient involvement.

Results

The search results are reported in Figure 1: 1238 articles were identified for abstract review. Twenty-six articles were selected as 'pearls'. Two hundred and eight further articles were identified during the citation search and sixty three from the reference search. Two hundred and thirty four articles were excluded as duplicates, review articles, not related to PsA and not related to the development of an outcome measure. Thus, sixty three articles were selected for final inclusion, summarised in Table 1.

Six articles described some patient involvement. Only one outcome measure, the Psoriatic Arthritis Quality of Life (PsAQoL), described patient involvement during the initial development stage.¹⁵ In this study the patients involvement was proportional and acknowledged but there was no evidence of patient selection, training or on-going collaboration in the tools refinement. Two further studies involved patients in the assessment (but not development of) existing measures.^{16, 17}

Three articles reported the involvement of four patients during the development of the OMERACT core set for PsA. There were no patients at the first OMERACT 7 workshop where PsA domains were first discussed. Deliberations were based on two previous GRAPPA exercises to identify domains, a Delphi process³ and a nominal group process⁸. The Delphi processes included thirty two rheumatologists and no patients. The group process included three groups reported to contain representatives from rheumatology, dermatology, patients and industry sponsors (without a vote) but exact numbers were not reported or available from records. As a result of these deliberations, a set of domains was identified. This data was reviewed in the OMERACT 7 workshop before participants were divided into twelve groups to discuss domains that should be included in PsA clinical trials. Domains suggested were then voted on and summarised into a summary table and presented at a plenary session. The final consensus on a core set of domains was made at OMERACT 8. One patient of four with PsA presented a personal story of living with PsA at this meeting amongst 137 physicians. After a plenary session at which current status of measures used

to assess PsA were reviewed, and discussion at breakout groups, the group achieved consensus on six domains for the inner circle of the core set.

In summary this systematic review establishes that much of the original domain construct, outcome measure, disease activity and responder indices were developed and prioritised without substantial incorporation of the patient perspective.

PIOMPSA Special Interest Group

The PIOMPSA Special Interest Group (SIG) was formed as part of a GRAPPA initiative to address the historic lack of patient involvement in the development of PsA outcome measures. The group brings together seven rheumatologists (AA, LC, OF, LG, PH, NJM and WT) one professor of rheumatology nursing (SH), one nurse practitioner (PM) and six representatives of the patient perspective (MB, WC, JJ, AR, DO'S and MdeW). The group had representatives from the UK, Ireland, Canada, France and the Netherlands.

Proceedings of the first PIOMPSA meeting

The first step was an initial meeting held in Dublin in August 2012. The aim of this meeting was to agree on a preliminary roadmap for involving the patient perspective in the further development of outcome measures and domains of PsA, with a view of incorporating this in an OMERACT 14 workshop proposal.

To this end a meeting was convened and introductory presentations were made to facilitate group discussion.

Introductory presentations

MdeW reviewed the role of patients in research, describing the opportunities for patient involvement at each step of the research process from design through to implementation and reporting. The EULAR recommendations clarify how this may be achieved including the roles patients may take, numbers, recruitment, selection, support, training and acknowledgment.¹²

NJM reviewed the OMERACT core set of domains and the tools to measure them in PsA studies.² He highlighted the importance of PRO's as a reliable, patient centred, feasible and sustainable method of data collection in longitudinal observational studies. The importance of physician measures such as the joint count and skin score were also recognised but that they require relatively high levels of training. NJM indicated that the level of patient participation in the development of any existing measures or domains was likely to have been minimal and that there was a need for this to be established with a systematic review. PH discussed the role of composite measures as a method of capturing all aspects of disease activity in PsA. There is a lack of consensus currently on the three novel measures: the Composite Psoriatic Disease Activity Index (CPDAI), the Arithmetic Means of Desirability Functions (AMDF) and the Psoriatic Arthritis Disease Activity Score (PASDAS). Again it was felt likely there had been minimal patient involvement in the development of these scores. PM discussed the importance of fatigue as an outcome measure in RA and PsA but

acknowledged there was a current lack of a validated tool to use in PsA and that further research was required. Two studies developing novel instruments currently underway are incorporating the patient perspective; the Psoriatic Arthritis Impact of Disease (PsAID) study¹⁸ and the disease flare initiative.

Group discussions

Whilst it was recognised that all domains are important on an individual basis some may not be sufficiently responsive to change to warrant inclusion in an activity measure. Conversely domains that are subject to little variation may not be suitable as response measures and better incorporated 'impact' or severity measures. There was a feeling amongst the group that despite these variances all items should be tracked as part of the research agenda.

There was recognition that some aspects of disease important to patients are not currently included in the existing composite measures (fatigue, pain, work, participation) and it was agreed that the patient perspective was essential in justifying the inclusion and exclusion of individual items. The patient participants wondered what rationales are behind the novel composite measures and why these scores do not include all OMERACT PsA core domains. The group summarised with the following agreements and action plan:

- There was a need to definitively confirm the level of patient involvement in outcome measure and domain development with a systematic review.

- In order to inform a roadmap to improve future patient involvement the group should meet again to review;
 - The OMERACT experience of incorporating the patient perspective in choosing and developing instruments in RA.
 - The findings of the systematic review.
 - The preliminary findings of the PsAID project and Flare studies

Proceedings of the Bath follow up meeting

The meeting took the following structure; MdeW prepared pre-meeting reading material for all members of the group covering the project background, concepts of outcome measurement, OMERACT and its process and a glossary of terminology, introductory presentations were made to inform discussions and concluded in a summary action plan.

Introductory presentations

OF reviewed the Dublin meeting outcomes and the group discussed the opportunity of raising the issue of improved patient participation at GRAPPA through a workshop at the forthcoming Toronto meeting. AA drew the groups' attention to INVOLVE, a UK based body promoting patient involvement in the NHS and particularly research.¹⁴ This national profile for patient involvement was further support for the PIOMPSA groups' objectives.

MdeW presented a patients perspective of ten years involvement with OMERACT. He outlined the need to understand the impact of disease through the patient perspective before selecting domains, a core set, tools for

measurement and cut off values for treatment response. Layered into this process he described the historic discrepancies between the physician and patient perspectives of disease activity. Fatigue was used as an example of an outcome important to patients, but not included in the existing inner circle of the OMERACT core set that was selected and prioritised by physicians. Finally he drew attention to the poor reporting of the core set and the importance that all domains are reported with none left out, as recently systematically reviewed by Palominos *et al.*⁴ Discussions ensued on the importance of individual domains, the historic omission of fatigue and the on-going development of the Bristol Rheumatoid Arthritis Fatigue (BRAf) scale.

AA raised the potential issue of how disagreement between physicians and patients in prioritising domains for core-sets or composite measures would be addressed. LC used the RA flare group experience to describe a method of avoiding conflict and achieving agreement through a Delphi process of ranking and consensus to incorporate all perspectives.

PH presented the preliminary findings from the PsAID¹⁸ and Flare studies (unreported findings). The EULAR PsAID initiative was conceived from the belief that the patient perspective is not fully reflected in existing tools and has the aim of addressing this through appropriate involvement during the development of a new disease impact measure, the PsAID. The group is made up of patients, rheumatologists, dermatologists and allied health professionals from 13 countries. He went on to describe the study starting with the identification and selection of sixteen domains identified by patients at

the first meeting. The domains were then prioritised by a ranking exercise including more than 130 patients. After excluding four domains with low scores in the ranking exercise two weighting systems were employed to create two versions, one for nine domains and one for twelve. A longitudinal study of >400 patients in thirteen countries found the feasibility, reliability and sensitivity of the two tools to be good.¹⁸

PH then went on to discuss the Flare study. Flare is a very different experience for every patient and there is a need for a standardised definition. SH led on an international qualitative study that identified the core elements of RA flare, which prompted discussion from the patient representatives in the group on the experience of flare.¹⁹ The local Bath PsA group (named PsAZZ) meet to exchange views and flare had recently been discussed. The group emphasised the importance of two particular aspects of flare; the systemic feelings of ill health found in flare dubbed the 'yuk factor' and ability to work.

WT presented the findings of the systematic literature review. The group went on to discuss how the patient perspective may influence the existing domain selection and outcome measures.

Group discussion on the OMERACT core set of PsA domains

The group posed the question that in light of the findings of the very low levels of patient involvement identified in the systematic review was it necessary to review the core domains and the tools to measure them? Were there domains that were not included in the inner circle that perhaps should be, such as

dactylitis and fatigue?² It was noted that there was little difference in the scores at OMERACT 8 between those domains finally included in the inner circle and those not.² Originally only domains with validated measures were included in the inner circle leaving those without to the outer circle or research agenda. The group discussed the examples of fatigue and dactylitis.

The domain of fatigue had caused much debate at the OMERACT workshops but was finally placed in the outer circle because there was no agreed instrument to measure it. Since OMERACT 8 there has been considerable work in the development of many outcomes in PsA which may influence the ranking of domains.² The patients in the group commented that although fatigue had been identified as an important outcome from the patient perspective, and despite the fact that a validated instrument was lacking, no research was initiated at that stage to develop a measure of fatigue in PsA. Moreover the evidence that will be reported in the PsAID study suggests fatigue ranks third of sixteen domains behind pain and skin disease from the patient perspective indicating its place in the core set may need to be reconsidered. However, a validated instrument to measure fatigue in PsA is still lacking.

The group felt that it was important to reconsider the place of dactylitis in the core set, currently in the outer circle. It was suggested that the measurement of dactylitis is covered through within the existing joint count or within the assessment of physical function, both included in the inner circle, and as such separate measurement was not required. An alternate view point voiced by

the group was that dactylitis is a characteristic and frequent manifestation of PsA rarely seen in other diseases so specific measurement is warranted. Additionally there is a validated measure available in the Leeds Dactylitis Index (LDI) for its measurement.²⁰

The group then posed the question; should domain selection be based on areas affecting 'a significant proportion' of patients as in the RA model? Whilst this seems reasonable to include domains affecting a significant proportion of patients there was agreement that this approach was flawed in PsA. The variable clinical phenotype may mean such an approach would miss disease activity amongst those affected in less common domains. Furthermore if treatment decisions are being made on the basis of core set outcome measures the domains included become critically important.

In summary there was a feeling that all important domains should be included in the core set thereby forcing the development of appropriate measures and that this proposal should be taken forward for discussion at the GRAPPA Toronto Workshop.

Outcome measurement

There are many measures now available for the measurement of domains in the inner circle of the OMERACT core set but a lack of consensus on which were most discriminatory. The advantages and limitations of the currently available measures, including the novel composite indices were outlined by physicians within the group. By example the advantages of composite

measures were outlined, including; the ability to capture multiple domains, better quantification of the total burden of disease in someone with low activity but in multiple domains and their sensitivity to change enabling smaller, less expensive and quicker studies. Limitations include factors such as; they are often time consuming to complete, require training and have the potential of masking fluctuation in a single disease area by other domains. PH introduced the idea that the arithmetically derived AMDF could be adapted to incorporate different domains to reflect changes in the inner circle of the core set then be re-validated. The group proposed that there may be a need for a minimal 'inner circle' composite index and a second 'expanded' composite to incorporate broader domains. The possibility of revising the CPDAI, with patient involvement, was also discussed including the possibility of expanding the index to include a patient global score.

The group discussed the lack of objective evidence that incorporating the patient perspective improves outcome measures. Such a study would be very difficult to design and taken with the theoretical advantages is arguably not required. Perhaps the first argument is that incorporating the patient perspective ensures that PsA outcomes research remains patient centred. An example of the success of this approach may be found in the improved profile and measurement of fatigue in RA.¹³ Furthermore there are advantages on individual and group/ association level whereby patients may feel a greater sense of empowerment through more involvement with research.²¹ Such relationships may bring additional advantages such as improved participation in future research projects and the implementation of research findings.

The group acknowledged difficulties in incorporating the patient perspective.¹² In summary these include, but are not limited to; overcoming the asymmetrical nature of the physician/ patient relationship and the importance of creating a supportive and equal partnership; achieving 'representativeness' of the patient perspective through appropriate selection of patients and finally avoidance of relying solely on long term patient partners who may become professional with time thereby bring another medical opinion rather than the true patient perspective.

Conclusion

We report a systematic review of patient involvement in the development of outcome measures and domains in PsA together with the proceedings of the first meetings of the PIOMPSA group. We have outlined the background and aims of this special interest group together with discussion around the potential advantages and difficulties of incorporating the patient perspective in developing instruments for measuring disease outcome. These group discussions have identified research topics around domain selection and outcome measurement where the patient perspective may influence future research. The group concluded with agreement on the following action points;

- There is a historic underrepresentation of the patient perspective in the development of PsA domain selection and outcome measures, demonstrated in this systematic review and discussions.

- Ideas introduced in the PIOPMSA meetings could be refined in a GRAPPA special interest group with voting on a roadmap for achieving meaningful incorporation of the patient perspective in future research.
- There is a case for reviewing the OMERACT PsA core set with meaningful patient representation.
- The AMDF or CPDAI could be revised to incorporate domains included in the inner circle.

Conflicts of interest

AA, MB, LC, WC, OF, SH, PH, JJ, PM, AR, WT, MdeW have no conflicts of interest to declare. LG Received EULAR funding for the PsAID study.

Funding

Meetings were supported through unrestricted educational grants from Pfizer Ltd and Abbvie laboratories Ltd

Table 1: Systematic literature review of PsA outcome measures by domain

Core set	Domain	Outcome	Primary article (number of Pubmed citations)	Articles included from the Citation/ Reference search
Inner circle	Physical function	HAQ	<i>Blackmore 1995 (11)²²</i>	Pincus 1999 ²³ Husted 1995/ 2001/5/7 ²⁴⁻²⁷ Leung 2008 ²⁸ Brodsky 2010 ²⁹ Mease- 2011 ³⁰ Kwok2010 ³¹ Wolfe 2004 ³² MacKenzie 2011 ¹⁷ Daltroy 1990 ³³ Stamm 2007 ¹⁶ Stamm 2007 ¹⁶ Taylor 2007 ³⁵ Husted 2001 ²⁴ Leung 2010/ 08 ^{28, 36} Kvamme 2009 ³⁷ MacKenzie 2011 ¹⁷
		SF36	<i>Husted 1997(11)³⁴</i>	Shikiar 2003 ³⁸ Husted 1996 ⁴⁰ Duffy 1992 ⁴¹ Stamm 2007 ¹⁶ Brodsky 2010 ²⁹ Singh 2009 ⁴³ Kvamme 2009 ³⁷ MacKenzie 2011 ¹⁷
		AIMS	<i>Husted 1996 (5)³⁹</i>	Shikiar 2003 ³⁸ Husted 1996 ⁴⁰ Duffy 1992 ⁴¹ Stamm 2007 ¹⁶ Brodsky 2010 ²⁹ Singh 2009 ⁴³ Kvamme 2009 ³⁷ MacKenzie 2011 ¹⁷
	Health related Quality of Life	EQ5D	<i>Sokoll 2001 (22)⁴²</i>	Shikiar 2003 ³⁸ Husted 1996 ⁴⁰ Duffy 1992 ⁴¹ Stamm 2007 ¹⁶ Brodsky 2010 ²⁹ Singh 2009 ⁴³ Kvamme 2009 ³⁷ MacKenzie 2011 ¹⁷
		PsAQoI	<i>McKenna 2004 (9)¹⁵</i>	Shikiar 2003 ³⁸ Stamm 2007 ¹⁶ Brodsky 2010 ²⁹ Healy 2008 ⁴⁴ Billing 2010 Stamm 2007 ¹⁶ MacKenzie 2011 ¹⁷ Shikiar 2003 ³⁸
		DLQI	<i>Nicol 1996 (4)⁴⁵</i>	Shikiar 2003 ³⁸
		ASQUoI	<i>Nil in PsA</i>	
	Patient global	Patient global VAS/ Numeric	<i>Cauli 2011 (0)⁴⁶</i>	Kwok 2010 ³¹ Leung 2012 ⁴⁷ Dandorfer 2012 ⁷ Nil
	Peripheral joint activity	Joint count	<i>Gladman 2007 (5)⁴⁸</i>	
	Skin activity	PASI	<i>Fredriksson 1974(64)⁴⁹</i>	Louden 2004 ⁵⁰ Feldman 1996 ⁵¹ Shikiar 2003 ³⁸ Carlin 2004 ⁵² Nil
	Pain	Pain VAS	<i>Kwok 2010 (1)³¹</i>	Nil
Outer circle	Physician global	PGA	<i>Nil in PsA</i>	Nil
		BASFI	<i>Leung 2008 (2)²⁸</i>	MacKenzie 2011 ¹⁷
	Fatigue	FACIT-fatigue	<i>Chandran 2007 (4)</i>	Nil
		LEI	<i>Healy 2008- (3)⁵³</i>	Nil
	Enthesitis	MASES	<i>Gladman 2007 (5)⁴⁸</i>	Nil
		SPARCC	<i>Maksymowych 2009 (3)⁵⁴</i>	Gladman 2007 ⁵⁵
	Dactylitis	LDI	<i>Helliwell 2005 (1)⁵⁶</i>	Healy 2000 ⁷⁰ Gladman 2007 ⁴⁸
	Spinal	BASMI	<i>Gladman 2007 (3)⁵⁵</i>	Leung 2011 ⁵⁷ Fernandez-Sueiro 2009 ⁵⁸ Stamm 2007 ¹⁶ Leung 2008 ²⁸ Fernandez-sueiro 2010 ⁶⁰ Eder 2010 ⁶¹ MacKenzie 2011 ¹⁷
		BASDAI	<i>Taylor 2004 (2)⁵⁹</i>	Aktan 2007 ⁶³ Cassell 2007 ⁶⁴ Maejima 2010 ⁶⁵
	Nails	NAPSI/ mNAPSI	<i>Rich 2003 nil (4)⁶²</i>	
Research agenda	Participation			
OMERACT core set	Core domains		<i>Gladman 2007 (4)²</i>	Taylor 2005 ³ Gladman 2005 ⁸ Gladman 2005 ⁶⁶
Composite measures	Composite measures	CPDAI	<i>Mumtaz 2011 (0)⁶⁷</i>	Fitzgerald2012 ⁶⁸
		DAPSA/ DAREA	<i>Nell-Duxneuner 2010 (1)⁶⁹</i>	<i>Schoels 2010 (1)⁷⁰</i>
		MDA	<i>Coates 2010 (0)⁷¹</i>	Coates 2010 ⁷² Coates 2010 ⁷³
		PsAJAI	<i>Gladman 2010- 1892-7 (1)⁷⁴</i>	Gladman 2010 ⁷⁵ Nell-duxneuner 2010 ⁶⁹
		PASDAS & AMDF	<i>Helliwell 2012 (0)⁷⁶</i>	Nil

References

- **de Wit 2011. The EULAR recommendations for incorporating the patients' perspective in scientific research developed by patient partners, rheumatologists and allied health professionals.¹²
- **Gossec 2013. The development and preliminary validation of the PsA impact of disease (PsAID) project. This novel measure has been developed in close collaboration with patient partners.¹⁸
- *Bingham 2012. An editorial concisely describing the rationale and evidence for incorporating the patient perspective in measuring rheumatoid arthritis flares.²¹
- *Palominos 2012. A systematic review demonstrating great heterogeneity in the reporting of outcomes in PsA clinical trials and the need for consensus on the reporting of PsA domains.⁴
- *Dandorfer 2012. A study demonstrating the discrepancies between physician and patient perspective of PsA.⁷

1. Mease PJ. Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI), Psoriatic Arthritis Quality of Life (PsAQOL), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Psoriatic Arthritis Response Criteria (PsARC), Psoriatic Arthritis Joint Activity Index (PsAJAI), Disease Activity in Psoriatic Arthritis (DAPSA), and Composite Psoriatic Disease Activity Index (CPDAI). *Arthritis Care Res (Hoboken)*. 2011;63 Suppl 11:S64-85.
2. Gladman DD, Mease PJ, Strand V, et al. Consensus on a core set of domains for psoriatic arthritis. *J Rheumatol*. 2007;34(5):1167-70.
3. Taylor WJ. Preliminary identification of core domains for outcome studies in psoriatic arthritis using Delphi methods. *Ann Rheum Dis*. 2005;64 Suppl 2:ii110-2.
4. Palominos PE, Gaujoux-Viala C, Fautrel B, et al. Clinical outcomes in psoriatic arthritis: A systematic literature review. *Arthritis Care Res (Hoboken)*. 2012;64(3):397-406.
5. Berkanovic E, Hurwicz ML, Lachenbruch PA. Concordant and discrepant views of patients' physical functioning. *Arthritis care and research : the official journal of the Arthritis Health Professions Association*. 1995;8(2):94-101.
6. Studenic P, Radner H, Smolen JS, et al. Discrepancies between patients and physicians in their perceptions of rheumatoid arthritis disease activity. *Arthritis Rheum*. 2012;64(9):2814-23.
7. Dandorfer SW, Rech J, Manger B, et al. Differences in the patient's and the physician's perspective of disease in psoriatic arthritis. *Semin Arthritis Rheum*. 2012;42(1):32-41.
8. Gladman DD. Consensus exercise on domains in psoriatic arthritis. *Ann Rheum Dis*. 2005;64 Suppl 2:ii113-4.
9. Kirwan JR, Fries JF, Hewlett SE, et al. Patient perspective workshop: moving towards OMERACT guidelines for choosing or developing instruments to measure patient-reported outcomes. *J Rheumatol*. 2011;38(8):1711-5.
10. Kirwan JR, Fries JF, Hewlett S, et al. Patient perspective: choosing or developing instruments. *J Rheumatol*. 2011;38(8):1716-9.
11. de Wit M, Abma T, Koelewijn-van Loon M, et al. Involving patient research partners has a significant impact on outcomes research: a responsive evaluation of the international OMERACT conferences. *BMJ open*. 2013;3(5).
12. de Wit MP, Berlo SE, Aanerud GJ, et al. European League Against Rheumatism recommendations for the inclusion of patient representatives in scientific projects. *Ann Rheum Dis*. 2011;70(5):722-6.
13. Kirwan JR, Hewlett SE, Heiberg T, et al. Incorporating the patient perspective into outcome assessment in rheumatoid arthritis--progress at OMERACT 7. *J Rheumatol*. 2005;32(11):2250-6.
14. NIHR. Briefing notes for researchers: public involvement in NHS, public health and social care research. National Institute for Health Research; 2012.
15. McKenna SP, Doward LC, Whalley D, et al. Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis. *Ann Rheum Dis*. 2004;63(2):162-9.

16. Stamm TA, Nell V, Mathis M, et al. Concepts important to patients with psoriatic arthritis are not adequately covered by standard measures of functioning. *Arthritis Rheum.* 2007;57(3):487-94.
17. MacKenzie H, Thavaneswaran A, Chandran V, et al. Patient-reported outcome in psoriatic arthritis: a comparison of Web-based versus paper-completed questionnaires. *J Rheumatol.* 2011;38(12):2619-24.
18. Gossec L dWM, Heiberg T, Maccarone M, Balanescu A, Balint P, Dora Niedermayer D, Cañete J, Lombarte A, Helliwell P, Parkinson A, Kalyoncu K, Kilic L, Braun J, Kiltz U, Otsa K, Veale D, O'Sullivan D, de Vlam K, Scrivo R, Stamm T, Carton L, Bertheussen H, Kvien T, On behalf of the PsAID Taskforce. Elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire. A 13-country EULAR initiative with involvement of patient research partners from each country. EULAR; Madrid2013. p. OP0111.
19. Hewlett S, Sanderson T, May J, et al. 'I'm hurting, I want to kill myself': rheumatoid arthritis flare is more than a high joint count--an international patient perspective on flare where medical help is sought. *Rheumatology (Oxford).* 2012;51(1):69-76.
20. Healy PJ, Helliwell PS. Measuring dactylitis in clinical trials: which is the best instrument to use? *J Rheumatol.* 2007;34(6):1302-6.
21. Bingham CO, 3rd, Alten R, de Wit MP. The importance of patient participation in measuring rheumatoid arthritis flares. *Ann Rheum Dis.* 2012;71(7):1107-9.
22. Blackmore MG, Gladman DD, Husted J, et al. Measuring health status in psoriatic arthritis: the Health Assessment Questionnaire and its modification. *J Rheumatol.* 1995;22(5):886-93.
23. Pincus T, Swearingen C, Wolfe F. Toward a multidimensional Health Assessment Questionnaire (MDHAQ): assessment of advanced activities of daily living and psychological status in the patient-friendly health assessment questionnaire format. *Arthritis Rheum.* 1999;42(10):2220-30.
24. Husted JA, Gladman DD, Farewell VT, et al. Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis. *Arthritis Rheum.* 2001;45(2):151-8.
25. Husted JA, Gladman DD, Long JA, et al. A modified version of the Health Assessment Questionnaire (HAQ) for psoriatic arthritis. *Clin Exp Rheumatol.* 1995;13(4):439-43.
26. Husted JA, Tom BD, Farewell VT, et al. Description and prediction of physical functional disability in psoriatic arthritis: a longitudinal analysis using a Markov model approach. *Arthritis Rheum.* 2005;53(3):404-9.
27. Husted JA, Tom BD, Farewell VT, et al. A longitudinal study of the effect of disease activity and clinical damage on physical function over the course of psoriatic arthritis: Does the effect change over time? *Arthritis Rheum.* 2007;56(3):840-9.
28. Leung YY, Tam LS, Kun EW, et al. Comparison of 4 functional indexes in psoriatic arthritis with axial or peripheral disease subgroups using Rasch analyses. *J Rheumatol.* 2008;35(8):1613-21.
29. Brodsky V, Pentek M, Balint PV, et al. Comparison of the Psoriatic Arthritis Quality of Life (PsAQoL) questionnaire, the functional status (HAQ) and utility (EQ-5D) measures in psoriatic arthritis: results from a cross-sectional survey. *Scandinavian journal of rheumatology.* 2010;39(4):303-9.
30. Mease PJ, Woolley JM, Bitman B, et al. Minimally important difference of Health Assessment Questionnaire in psoriatic arthritis: relating thresholds of

- improvement in functional ability to patient-rated importance and satisfaction. *J Rheumatol.* 2011;38(11):2461-5.
31. Kwok T, Pope JE. Minimally important difference for patient-reported outcomes in psoriatic arthritis: Health Assessment Questionnaire and pain, fatigue, and global visual analog scales. *J Rheumatol.* 2010;37(5):1024-8.
 32. Wolfe F, Michaud K, Pincus T. Development and validation of the health assessment questionnaire II: a revised version of the health assessment questionnaire. *Arthritis Rheum.* 2004;50(10):3296-305.
 33. Daltroy LH, Larson MG, Roberts NW, et al. A modification of the Health Assessment Questionnaire for the spondyloarthropathies. *J Rheumatol.* 1990;17(7):946-50.
 34. Husted JA, Gladman DD, Farewell VT, et al. Validating the SF-36 health survey questionnaire in patients with psoriatic arthritis. *J Rheumatol.* 1997;24(3):511-7.
 35. Taylor WJ, McPherson KM. Using Rasch analysis to compare the psychometric properties of the Short Form 36 physical function score and the Health Assessment Questionnaire disability index in patients with psoriatic arthritis and rheumatoid arthritis. *Arthritis Rheum.* 2007;57(5):723-9.
 36. Leung YY, Ho KW, Zhu TY, et al. Testing scaling assumptions, reliability and validity of medical outcomes study short-form 36 health survey in psoriatic arthritis. *Rheumatology (Oxford).* 2010;49(8):1495-501.
 37. Kvamme MK, Kristiansen IS, Lie E, et al. Identification of cutpoints for acceptable health status and important improvement in patient-reported outcomes, in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. *J Rheumatol.* 2010;37(1):26-31.
 38. Shikier R, Willian MK, Okun MM, et al. The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study. *Health and quality of life outcomes.* 2006;4:71.
 39. Husted J, Gladman DD, Farewell VT, et al. Validation of the revised and expanded version of the Arthritis Impact Measurement Scales for patients with psoriatic Arthritis. *J Rheumatol.* 1996;23(6):1015-9.
 40. Husted J, Gladman DD, Long JA, et al. Relationship of the Arthritis Impact Measurement Scales to changes in articular status and functional performance in patients with psoriatic arthritis. *J Rheumatol.* 1996;23(11):1932-7.
 41. Duffy CM, Watanabe Duffy KN, Gladman DD, et al. The utility of the arthritis impact measurement scales for patients with psoriatic arthritis. *J Rheumatol.* 1992;19(11):1727-32.
 42. Sokoll KB, Helliwell PS. Comparison of disability and quality of life in rheumatoid and psoriatic arthritis. *J Rheumatol.* 2001;28(8):1842-6.
 43. Singh JA, Strand V. Health care utilization in patients with spondyloarthropathies. *Rheumatology (Oxford).* 2009;48(3):272-6.
 44. Healy PJ, Helliwell PS. Psoriatic arthritis quality of life instrument: an assessment of sensitivity and response to change. *J Rheumatol.* 2008;35(7):1359-61.
 45. Nichol MB, Margolies JE, Lippa E, et al. The application of multiple quality-of-life instruments in individuals with mild-to-moderate psoriasis. *PharmacoEconomics.* 1996;10(6):644-53.
 46. Cauli A, Gladman DD, Mathieu A, et al. Patient global assessment in psoriatic arthritis: a multicenter GRAPPA and OMERACT study. *J Rheumatol.* 2011;38(5):898-903.

47. Leung YY, Ho KW, Zhu TY, et al. Construct validity of the modified numeric rating scale of patient global assessment in psoriatic arthritis. *J Rheumatol*. 2012;39(4):844-8.
48. Gladman DD, Inman RD, Cook RJ, et al. International spondyloarthritis interobserver reliability exercise--the INSPIRE study: II. Assessment of peripheral joints, enthesitis, and dactylitis. *J Rheumatol*. 2007;34(8):1740-5.
49. Fredriksson T, Pettersson U. Severe psoriasis--oral therapy with a new retinoid. *Dermatologica*. 1978;157(4):238-44.
50. Louden BA, Pearce DJ, Lang W, et al. A Simplified Psoriasis Area Severity Index (SPASI) for rating psoriasis severity in clinic patients. *Dermatol Online J*. 2004;10(2):7.
51. Feldman SR, Fleischer AB, Jr., Reboussin DM, et al. The self-administered psoriasis area and severity index is valid and reliable. *J Invest Dermatol*. 1996;106(1):183-6.
52. Carlin CS, Feldman SR, Krueger JG, et al. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. *J Am Acad Dermatol*. 2004;50(6):859-66.
53. Healy PJ, Helliwell PS. Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis. *Arthritis Rheum*. 2008;59(5):686-91.
54. Maksymowych WP, Mallon C, Morrow S, et al. Development and validation of the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index. *Ann Rheum Dis*. 2009;68(6):948-53.
55. Gladman DD, Inman RD, Cook RJ, et al. International spondyloarthritis interobserver reliability exercise--the INSPIRE study: I. Assessment of spinal measures. *J Rheumatol*. 2007;34(8):1733-9.
56. Helliwell PS, Firth J, Ibrahim GH, et al. Development of an assessment tool for dactylitis in patients with psoriatic arthritis. *J Rheumatol*. 2005;32(9):1745-50.
57. Leung YY, Ho KW, Tam LS, et al. Evaluation of spinal mobility measurements in predicting axial psoriatic arthritis. *Clin Rheumatol*. 2011;30(9):1157-62.
58. Fernandez-Sueiro JL, Willis A, Pertega-Diaz S, et al. Evaluation of ankylosing spondylitis spinal mobility measurements in the assessment of spinal involvement in psoriatic arthritis. *Arthritis Rheum*. 2009;61(3):386-92.
59. Taylor WJ, Harrison AA. Could the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) be a valid measure of disease activity in patients with psoriatic arthritis? *Arthritis Rheum*. 2004;51(3):311-5.
60. Fernandez-Sueiro JL, Willis A, Pertega-Diaz S, et al. Validity of the bath ankylosing spondylitis disease activity index for the evaluation of disease activity in axial psoriatic arthritis. *Arthritis Care Res (Hoboken)*. 2010;62(1):78-85.
61. Eder L, Chandran V, Shen H, et al. Is ASDAS better than BASDAI as a measure of disease activity in axial psoriatic arthritis? *Ann Rheum Dis*. 2010;69(12):2160-4.
62. Rich P, Scher RK. Nail Psoriasis Severity Index: a useful tool for evaluation of nail psoriasis. *J Am Acad Dermatol*. 2003;49(2):206-12.
63. Aktan S, Ilknur T, Akin C, et al. Interobserver reliability of the Nail Psoriasis Severity Index. *Clin Exp Dermatol*. 2007;32(2):141-4.
64. Cassell SE, Bieber JD, Rich P, et al. The modified Nail Psoriasis Severity Index: validation of an instrument to assess psoriatic nail involvement in patients with psoriatic arthritis. *J Rheumatol*. 2007;34(1):123-9.

65. Maejima H, Taniguchi T, Watarai A, et al. Evaluation of nail disease in psoriatic arthritis by using a modified nail psoriasis severity score index. *Int J Dermatol*. 2010;49(8):901-6.
66. Gladman DD, Strand V, Mease PJ, et al. OMERACT 7 psoriatic arthritis workshop: synopsis. *Ann Rheum Dis*. 2005;64 Suppl 2:ii115-6.
67. Mumtaz A, Gallagher P, Kirby B, et al. Development of a preliminary composite disease activity index in psoriatic arthritis. *Ann Rheum Dis*. 2011;70(2):272-7.
68. FitzGerald O, Helliwell P, Mease P, et al. Application of composite disease activity scores in psoriatic arthritis to the PRESTA data set. *Ann Rheum Dis*. 2012;71(3):358-62.
69. Nell-Duxneuner VP, Stamm TA, Machold KP, et al. Evaluation of the appropriateness of composite disease activity measures for assessment of psoriatic arthritis. *Ann Rheum Dis*. 2010;69(3):546-9.
70. Schoels M, Aletaha D, Funovits J, et al. Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis. *Ann Rheum Dis*. 2010;69(8):1441-7.
71. Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. *Ann Rheum Dis*. 2010;69(1):48-53.
72. Coates LC, Cook R, Lee KA, et al. Frequency, predictors, and prognosis of sustained minimal disease activity in an observational psoriatic arthritis cohort. *Arthritis Care Res (Hoboken)*. 2010;62(7):970-6.
73. Coates LC, Helliwell PS. Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data. *Arthritis Care Res (Hoboken)*. 2010;62(7):965-9.
74. Gladman DD, Tom BD, Mease PJ, et al. Informing response criteria for psoriatic arthritis. I: discrimination models based on data from 3 anti-tumor necrosis factor randomized studies. *J Rheumatol*. 2010;37(9):1892-7.
75. Gladman DD, Tom BD, Mease PJ, et al. Informing response criteria for psoriatic arthritis (PsA). II: Further considerations and a proposal--the PsA joint activity index. *J Rheumatol*. 2010;37(12):2559-65.
76. Helliwell PS, FitzGerald O, Fransen J, et al. The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). *Ann Rheum Dis*. 2013;72(6):986-91.